A bipartisan group of senators plans to introduce a measure to give the FDA authority to approve follow-on versions of biotech drugs. The legislation from Democratic Sens. Edward Kennedy and Hillary Clinton and Republican Sens. Michael Enzi and Orrin Hatch allows for interchangeability of the follow-on biologic drugs but also gives biotechs four years of exclusivity before a generic maker can sell a biosimiliar and 12 years before a copycat version can go to market.
Published in Brief: